A drug currently used in Europe and Asia for treating gallstone-related spasms has been found effective in preventing the onset of Type-1 diabetes in mice, according to a study.
Researchers believe that a similar treatment may be effective in preventing the autoimmune disorder in humans too.
The study found that the buildup of a substance in the pancreas during the pre-symptomatic stage of Type-1 diabetes is essential to the development of the disease.
Administering a drug to block production of this substance stops damage to insulin-producing cells and prevents the onset of the autoimmune disorder, the findings showed.
The researchers earlier found that one substance, called hyaluronan, was overly abundant near the pancreatic beta cells of people with Type 1 diabetes.
"We wondered what would happen if we prevented that buildup," said the study's senior author Paul Bollyky, assistant professor of infectious diseases at Stanford University School of Medicine in California, US.
"And we knew a drug that does that," Bollyky noted.
The drug was hymecromone, or 4-methylumbelliferone (4-MU for short).
When the researchers initiated 4-MU treatment before the majority of the mice's beta cells had been wiped out, none of the mice developed excess glucose in their bloodstream.
Mice that did not get 4-MU did. If mice stayed on a 4-MU regimen, they remained diabetes-free for at least a year.
But if the regimen was stopped, they quickly became diabetic.
The researchers said they are now preparing for human trial to test the effectiveness of 4-MU in preventing Type-1 diabetes.
The study was published in the Journal of Clinical Investigation.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
